Protalex to start Phase Ib trial of immune thrombocytopenia drug in France
With the approval, the company now intends to begin the PRTX-100-203 trial at several sites in France with patient enrollment expected to start by this year end. Furthermore,
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako’s portfolio of companion diagnostics and the company’s leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1
Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. Under FDA’s accelerated approval regulations, this
The SOLUTION clinical study is designed to evaluate the efficacy and safety of Sollpura, a microbial derived, biotech pancreatic enzyme replacement therapy (PERT), compared to an approved, porcine-derived,